[{"orgOrder":0,"company":"Muvon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Muvon Therapeutics Announces Successful Phase I Clinical Study in Female Patients with Stress Urinary Incontinence Using a Novel Regenerative Cell Therapy","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Not Applicable","leadProduct":"Autologous Muscle Precursor Cell Therapy","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Phase I","graph3":"Muvon Therapeutics","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Muvon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Muvon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imbrium Therapeutics Completes First Patient Visit in Phase 1 Study of Potential Treatment for Interstitial Cystitis\/Bladder Pain Syndrome","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"IMB-150","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Phase I","graph3":"Imbrium Therapeutics","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Imbrium Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Imbrium Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Glycologix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Glycologix Treats First Patient in Pilot Study of GLX-100 for Treatment of Interstitial Cystitis\/Bladder Pain Syndrome","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"GLX-100","moa":"","url1":"","url2":"","graph1":"Urology","graph2":"Phase I","graph3":"Glycologix","amount2":0,"therapeuticAreaNew":"Urology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Urology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Glycologix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Glycologix \/ Not Applicable"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Details :
GLX-100 is a novel biopolymer, which has been designed to closely replicate the natural protective barrier layer and relieve the symptoms of Interstitial Cystitis/Bladder Pain Syndrome and Phase I results anticipated in 2024.
Details :
IMB-150 (also known as LYT-503) as a potential non-opioid treatment for female patients with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). IMB-150, is a novel formulation of lidocaine, and the clinical development program is called GainMe-IC.
Details :
To investigate safety and feasibility of a tissue-regenerative approach to treat stress urinary incontinence (SUI) in female patients with a novel transurethral injection therapy using autologous MPCs in a combination with NMES.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
September 08, 2022
Lead Product(s) :
Autologous Muscle Precursor Cell Therapy
Market Place
Reset All
